RxDoctor Payments Data

Binitha Joseph, MD

Internal Medicine · Oakdale, LANPI 1881893139

Payments from drug & device makers

$472in general payments, 2019–2025

Across 27 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$88
  • Lilly USA, LLC$81
  • Novo Nordisk$71
  • AstraZeneca$53
  • Novartis$32
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$30
  • plus $116 from 6 others

What the payments were for

  • Food & beverage$472100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$472 in reported general payments places this provider in the 50th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$169,866
Medicare patients
664
Services billed
1,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide147$178,571
JardianceEmpagliflozin137$101,338
FarxigaDapagliflozin Propanediol140$96,516
EliquisApixaban220$90,841
TradjentaLinagliptin114$60,529
RybelsusSemaglutide37$43,431
EntrestoSacubitril/Valsartan65$38,262
TrulicityDulaglutide32$38,147
Breztri AerosphereBudesonide/Glycopyr/Formoterol42$29,551
LinzessLinaclotide31$26,688
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$24,259
MounjaroTirzepatide18$20,694
MyrbetriqMirabegron21$20,575
JanuviaSitagliptin Phosphate25$19,548
Tresiba Flextouch U-200Insulin Degludec18$18,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Tresiba, Novolog$71$230,568239 claims
AstraZenecaFarxiga, Breztri Aerosphere$53$126,067182 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$81$61,60586 claims
NovartisEntresto$32$38,26265 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$19$37,51152 claims
AbbVieLinzess$25$26,68831 claims
Johnson & JohnsonXarelto$88$16,51830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Oakdale

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →